Andrew Ip 1,2,*,† , Maciej Kabat 3,† , Lindsay Fogel 1,4 , Hassan Alkhatatneh 5 , Jason Voss 2, Amolika Gupta 4,6,
Alexandra Della Pia 2 , Lori A. Leslie 1,2 , Tatyana Feldman 1,2, Maher Albitar 7 and Andre H. Goy 1,2
1 Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA;
lindsay.fogel@hmhn.org (L.F.); lori.leslie@hmhn.org (L.A.L.); tatyana.feldman@hmhn.org (T.F.);
goy.andre@hmhn.org (A.H.G.)
2 John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ 07601, USA;
jason.voss@hmhn.org (J.V.); alexandra.dellapia@hmhn.org (A.D.P.)
3 Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ 07601, USA;
maciej.kabat@hmhn.org
4 Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
5 Jefferson Einstein Philadelphia Hospital, Philadelphia, PA 19141, USA; hassan.alkhatatneh@jefferson.edu
6 Inova Fairfax Hospital, Falls Church, VA 22042, USA
7 Genomic Testing Cooperative, Irvine, CA 92618, USA; maher.albitar@hmhn.org
* Correspondence: andrew.ip@hmhn.org
† These authors contributed equally to this work.
Simple Summary: This review article provides an update on the current knowledge surrounding mantle cell lymphoma (MCL), focusing on the disease’s complexity and heterogeneity, as well as its prognostic factors. Advancements in risk stratification scoring systems are reviewed, and the emerging role of genomic technologies and their potential to inform risk profiling are also highlighted. In addition, the article discusses novel therapies, including Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, which could become cornerstones of MCL treatment in the future.